Table 2 Ancillary features favouring either malignancy or benignity

• US visibility as discrete nodule

• Size stability > 2 years

• Subthreshold growth

• Size reduction

• Restricted diffusion

• Enhancement parallels blood pool

• Mild to moderate T2 hyperintensity

• Undistorted vessels

• Corona enhancement

• Iron in mass (more than liver)

• Fat sparing in solid mass

• Marked T2 hyperintensity

• Iron sparing in solid mass

• Hepato-biliary phase isointensity

• Transitional phase hypointensity

• Hepato-biliary phase hypointensity

• Non-enhancing “capsule”

• Nodule-in-nodule

• Mosaic architecture

• Blood products in mass

• Fat in mass, more than adjacent liver